explore -WSS

explore

author：entertainment 2025-09-27 23:53:04 - browse：525

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： 3 hurdles to bringing medical devices to the U.S. market

knowledge

WSS

Do masks work? RCTs can't tell us

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Weight bias in eating disorder treatment complicated by new weight loss drugs

Readout LOUD podcast: ESMO highlights & Roivant's big deal

All of Us, NIH's precision medicine initiative, gets a big boost

Disclosing genetic information: not as worrisome as once feared

hotspot

explore

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Ask STAT: What do you want to know about ChatGPT in medicine?

State Dept. review finds Biden bears some blame for Afghanistan failures

Donald Trump's relentless attacks on special counsel Jack Smith

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Travis Kelce and the trap of celebrity vaccine endorsements

State Dept. review finds Biden bears some blame for Afghanistan failures

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

United colonoscopy coverage change 'may cost lives,' doctors say

The battle over the Brookhaven Landfill on Long Island

explore

Bill would allow buprenorphine prescription for addiction via telehealth

What would happen to your eyes if you looked at the solar eclipse?

Medicare must police algorithms in Medicare Advantage, Dems say

Gene therapy has helped boys walk. Can scientists keep it that way?

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Paxlovid study fails to answer questions over benefit for broader groups

focus

hotspot

knowledge

entertainment